

HESKA CORP  
Form 8-K  
June 21, 2013

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934**

**June 17, 2013**

Date of Report (Date of earliest event reported)

**HESKA CORPORATION**

(Exact name of Registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction of  
incorporation)

**000-22427**  
(Commission File Number)

**77-0192527**  
(I.R.S. Employer Identification No.)

**3760 Rocky Mountain Avenue**

**Loveland, Colorado 80538**

(Address of principal executive offices) (Zip code)

**(970) 493-7272**

(Registrant's telephone number, including area code)

**Not Applicable**

(Former name or former address, if changed since last report)

**Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):**

**Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)**

**Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)**

**Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))**

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 1.01 Entry into a Material Definitive Agreement.**

On June 17, 2013, Diamond Animal Health, Inc. ( *Diamond* ), a wholly-owned subsidiary of Heska Corporation (the *Company* ), entered into an Asset Purchase and License Agreement (the *Agreement* ) with Elanco Animal Health, a division of Eli Lilly and Company ( *Elanco* ), pursuant to which, among other things, *Diamond* (i) sold certain non-core intellectual property and physical assets used in the production of both bovine and feline vaccines (the *Assets* ) to *Elanco*, (ii) licensed back from *Elanco* the right to use certain of the intellectual property sold to *Elanco* to manufacture products for *Elanco* and certain third parties, and (iii) upon the occurrence of certain events, agreed to negotiate in good faith a supply and distribution relationship pursuant to which *Diamond* will act as supplier and *Elanco* will act as distributor with respect to certain products to be sold in the U.S. (collectively, the *Elanco Transaction* ). The *Agreement* contains customary representations and warranties of the parties.

Following consummation of the *Elanco Transaction*, *Diamond* retained possession of certain *Assets* on behalf of *Elanco* for use by *Diamond* in the production of products for *Elanco* and certain third parties, subject to terms and conditions specified in the *Agreement*. Under certain conditions, *Elanco* has the right to have the *Assets* retained by *Diamond* transferred to *Elanco*. Additionally, *Elanco* has the right at any time during the *Agreement* to require *Diamond* to manufacture and provide to *Elanco* certain additional assets that are derived from the *Assets*. Both parties believe that the *Elanco Transaction* will maintain or increase throughput at *Diamond*'s wholly-owned manufacturing facility in Des Moines, Iowa (the *Manufacturing Facility* ) during the term of the *Agreement*.

The *Agreement* provides that *Elanco* will give notice to *Diamond* if *Elanco* develops any new product that incorporates any of the *Assets*. Under certain conditions, the parties agree to enter into exclusive, good faith negotiations for 60 days to have such new product manufactured by *Diamond* on behalf of *Elanco*, pursuant to terms and conditions acceptable to both parties. In addition, prior to the expiration of the *Agreement*, *Diamond* has the right to license certain portions of the *Assets* from *Elanco* for research and development purposes.

The term of the *Agreement* is ten years. The *Agreement* will automatically renew for two-year periods, unless two-year advance notice of termination is provided by either party. On or after the fifth anniversary of the effective date of the *Agreement*, *Elanco* may terminate the *Agreement* after providing three-year advanced notice and paying an early termination fee. *Diamond* may terminate the *Agreement* if a supply and distribution agreement is not consummated prior to a specific date or in the event that *Elanco* fails to make any payments required under the *Agreement*. Either party may terminate the agreement in the case of a breach of the *Agreement* or violation of law by the other party or in the case of bankruptcy, insolvency, dissolution or winding up of the other party. Prior to the expiration of the term, under certain circumstances, *Elanco* may also terminate certain licenses to *Diamond* relating to specified segments. In the event of termination or expiration of the *Agreement*, *Diamond* (i) is granted a license to use and sub-license certain intellectual property purchased by *Elanco*, and (ii) will have an option to acquire certain physical assets purchased by *Elanco* for a period of 90 days following such termination or expiration.

The *Agreement* grants *Elanco* (i) the right, at *Elanco*'s election at any time during the term of the *Agreement*, to enter into exclusive, good faith negotiations with *Diamond* for the purchase of the *Manufacturing Facility* for a period of 60 days, and (ii) a right of first refusal if *Diamond* receives an offer from a third party to acquire the *Manufacturing Facility*.

The *Agreement* also provides for the formation of a Steering Committee comprised of two members appointed by each party to meet at least annually with the goal of fostering a collaborative relationship between the parties. In addition, the Steering Committee is granted authority to administer the implementation of certain provisions of the *Agreement*.

A copy of the *Agreement* has been filed with this Current Report, with certain portions omitted pursuant to a request for confidential treatment. The foregoing description of the terms of the *Agreement* and the *Elanco Transaction* is not complete and is qualified in its entirety by reference to full and complete terms of the *Agreement*.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

<u>Exhibit No.</u>	<u>Description</u>
10	Asset Purchase and License Agreement, dated June 17, 2013, by and between Diamond Animal Health, Inc., a wholly-owned subsidiary of Heska Corporation, and Elanco Animal Health, a division of Eli Lilly and Company

Edgar Filing: HESKA CORP - Form 8-K

---

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

HESKA CORPORATION

a Delaware corporation

Dated: June 21, 2013

By: /s/ Jason A. Napolitano

Jason A. Napolitano

*Executive Vice President, Chief Financial Officer*

*and Secretary*

**Exhibit Index**

<u>Exhibit No.</u>	<u>Description</u>
10	Asset Purchase and License Agreement, dated June 17, 2013, by and between Diamond Animal Health, Inc., a wholly-owned subsidiary of Heska Corporation, and Elanco Animal Health, a division of Eli Lilly and Company